Patent intelligence · US
US 10105344
Methods of reducing blood lactate concentration
Methods of reducing blood lactate concentration
Patent details — US 10105344
- Jurisdiction
- US
- Status
- granted
- Grant date
- Oct 23, 2018
- Expiration
- Oct 18, 2038
- Applicant
- Stokely-Van Camp, Inc.
- Claims
- 19
- CPC classes
- A61K, A61K31/352, A61K9/0095, A61P
Quick answer
US 10105344 (Methods of reducing blood lactate concentration) is held by Stokely-Van Camp, Inc.. Status: granted. Granted Oct 23, 2018. Expires Oct 18, 2038 (12 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Stokely-Van Camp, Inc.
- Grant date
- Expiration
- Claims
- 19
- CPC classes
- A61K, A61K31/352, A61K9/0095, A61P, A61P21/00, A61P3/00
More from Stokely-Van Camp, Inc.
Related pharmaceutical patents in our USPTO index.
-
US 12338437
OPA1 antisense oligomers for treatment of conditions and diseases
granted -
US 12060558
Methods and compositions for treatment of cholesteryl ester storage disease
granted -
US 11873490
Antisense oligomers for treatment of conditions and diseases
granted -
US 11814622
OPA1 antisense oligomers for treatment of conditions and diseases
granted -
US 11096956
Antisense oligomers and uses thereof
granted -
US 11083745
Antisense oligomers for treatment of autosomal dominant mental retardation-5 and Dravet Syndrome
granted -
US 10913947
Antisense oligomers for treatment of conditions and diseases
granted -
US 10683503
Antisense oligomers for treatment of conditions and diseases
granted
Frequently asked questions
What is US patent 10105344?
US 10105344 (Methods of reducing blood lactate concentration) is held by Stokely-Van Camp, Inc.. Status: granted. Granted Oct 23, 2018. Expires Oct 18, 2038 (12 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 10105344?
Stokely-Van Camp, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 14 pharmaceutical patents for this assignee.
When does US 10105344 expire?
Our index shows an expiration date of Oct 18, 2038 (12 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.